Market Drivers: Key drivers include increasing prevalence of immunodeficiency disorders globally, rising demand for plasma-derived medicinal products, and a growing geriatric population. The market ...

The Franklin County Board of Commissioners has passed a resolution urging the Benton Franklin Health District (BFHD) to cease ...

US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Ixinity (trenonacog alfa) can effectively prevent and controlled bleeds in young children with severe or moderately severe ...

Columnist Jennifer Lynne stresses the significance of hidden symptoms in the lives of those with bleeding disorders.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.